Karyopharm Appoints Lori Macomber as Chief Financial Officer
Karyopharm Therapeutics Inc., a pharmaceutical company focused on innovative cancer therapies, has recently appointed Lori Macomber as its new Executive Vice President, Chief Financial Officer, and Treasurer. Effective January 3, 2025, Ms. Macomber will lead and direct the financial activities of the company.
According to Richard Paulson, President and CEO of Karyopharm, Lori’s extensive experience in strategic financial management and operations will play a crucial role in advancing the company’s strategy to grow XPOVIO revenue while maintaining disciplined expense management as they progress their clinical pipeline.
Ms. Macomber, with over 20 years of experience in leading growth and driving financial strategies for life science companies, has a proven track record in financial management from start-up to Fortune 500 companies. Her most recent role was serving as Chief Financial Officer at Legend Biotech Corporation.
As part of her appointment, effective January 31, 2025, Karyopharm granted Ms. Macomber inducement awards, including a non-statutory stock option to purchase 650,000 shares of Karyopharm’s common stock and 160,000 restricted stock units, under the Company’s 2022 Inducement Stock Incentive Plan. These awards are material to Ms. Macomber entering into employment with Karyopharm and will vest over four years.
Karyopharm Therapeutics Inc. specializes in developing oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Their lead compound, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. and marketed in several oncology indications. The company also has a pipeline targeted at various high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma.
For more information about Karyopharm Therapeutics Inc., visit their website at www.karyopharm.com, and follow them on LinkedIn. Please note that this press release contains forward-looking statements regarding the company’s clinical development plans and the potential regulatory submissions of selinexor.
